Core Laboratories Inc [CLB] stock is trading at $17.96, up 3.28%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The CLB shares have gain 8.32% over the last week, with a monthly amount drifted -7.14%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Core Laboratories Inc [NYSE: CLB] stock has seen the most recent analyst activity on June 30, 2023, when Citigroup downgraded its rating to a Sell and also revised its price target to $21 from $22. Previously, BofA Securities downgraded its rating to Underperform on April 18, 2023, and kept the price target unchanged to $21.50. On January 09, 2023, upgrade upgraded it’s rating to Neutral. Citigroup upgraded its rating to a Neutral and decreased its price target to $17 on October 07, 2022. Morgan Stanley downgraded its rating to a Underweight but $20 remained the price target by the analyst firm on September 26, 2022. Piper Sandler downgraded its rating to Underweight for this stock on April 18, 2022, and upped its price target to $21.30. In a note dated October 18, 2021, BofA Securities downgraded an Underperform rating on this stock and revised its target price from $36 to $32.
Core Laboratories Inc [CLB] stock has fluctuated between $13.82 and $25.13 over the past year. Currently, Wall Street analysts expect the stock to reach $25 within the next 12 months. Core Laboratories Inc [NYSE: CLB] shares were valued at $17.96 at the most recent close of the market. An investor can expect a potential return of 39.2% based on the average CLB price forecast.
Analyzing the CLB fundamentals
Core Laboratories Inc [NYSE:CLB] reported sales of 523.85M for the trailing twelve months, which represents a growth of 0.80%. Gross Profit Margin for this corporation currently stands at 0.38% with Operating Profit Margin at 0.11%, Pretax Profit Margin comes in at 0.09%, and Net Profit Margin reading is 0.06%. To continue investigating profitability, this company’s Return on Assets is posted at 0.05, Equity is 0.13 and Total Capital is 0.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.17.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 17.59 points at the first support level, and at 17.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.22, and for the 2nd resistance point, it is at 18.47.
Ratios To Look Out For
For context, Core Laboratories Inc’s Current Ratio is 2.32. Further, the Quick Ratio stands at 1.71, while the Cash Ratio is 0.2. Considering the valuation of this stock, the price to sales ratio is 1.61, the price to book ratio is 3.34 and price to earnings (TTM) ratio is 27.33.
